<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19877">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01742611</url>
  </required_header>
  <id_info>
    <org_study_id>1585-CL-0102</org_study_id>
    <nct_id>NCT01742611</nct_id>
  </id_info>
  <brief_title>Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis</brief_title>
  <official_title>ASP1585 Phase 3 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-labeled, non-comparative study to examine the safety and
      efficacy of ASP1585 for long-term dosing in chronic kidney disease patients with
      hyperphosphatemia not on dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time-course changes in serum phosphorus levels</measure>
    <time_frame>During 48 week treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement rate of  the target range of serum phosphorus level</measure>
    <time_frame>During 48 week treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve the target range of serum phosphorus level</measure>
    <time_frame>During 48 week treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-course changes in serum calcium levels</measure>
    <time_frame>During 48 week treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-course changes in serum intact PTH (parathyroid hormone) levels</measure>
    <time_frame>During 48 week treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, labo-tests and 12-lead ECGs</measure>
    <time_frame>During 48 week treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Renal Insufficiency</condition>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>ASP1585 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1585</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP1585 group</arm_group_label>
    <other_name>LY101</other_name>
    <other_name>AMG223</other_name>
    <other_name>bixalomer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who completed study 1585-CL-0101 or new patients who meet following criteria

          -  Chronic kidney disease patients (eGFR &lt; 60 mL/min/1.73 m2)

          -  Serum phosphorus measurement â‰§4.6 mg/dl, &lt;9.0 mg/dl

          -  Written informed consent

        Exclusion Criteria:

          -  Patients with gastrointestinal surgery or enterectomy

          -  Patients with severe cardiac diseases

          -  Patients with severe constipation or diarrhea

          -  Patients with a history or complication of malignant tumors

          -  Patients with uncontrolled hypertension

          -  Patients treated with parathyroid intervention
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Administration Dept.</last_name>
    <email>clintrialtrials_info@jp.astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 8, 2013</lastchanged_date>
  <firstreceived_date>December 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD</keyword>
  <keyword>Not on dialysis</keyword>
  <keyword>ASP1585</keyword>
  <keyword>Bixalomer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
